- Home
- GNRC vs ROIV Comparison
GNRC vs ROIV Comparison
Compare GNRC & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNRC
- ROIV
- Stock Information
- Founded
- GNRC 1959
- ROIV 2014
- Country
- GNRC United States
- ROIV United Kingdom
- Employees
- GNRC N/A
- ROIV N/A
- Industry
- GNRC Metal Fabrications
- ROIV Biotechnology: Pharmaceutical Preparations
- Sector
- GNRC Consumer Discretionary
- ROIV Health Care
- Exchange
- GNRC Nasdaq
- ROIV Nasdaq
- Market Cap
- GNRC 7.5B
- ROIV 7.8B
- IPO Year
- GNRC 2010
- ROIV N/A
- Fundamental
- Price
- GNRC $146.82
- ROIV $11.36
- Analyst Decision
- GNRC Buy
- ROIV Buy
- Analyst Count
- GNRC 18
- ROIV 4
- Target Price
- GNRC $170.72
- ROIV $17.50
- AVG Volume (30 Days)
- GNRC 1.0M
- ROIV 7.8M
- Earning Date
- GNRC 07-30-2025
- ROIV 08-07-2025
- Dividend Yield
- GNRC N/A
- ROIV N/A
- EPS Growth
- GNRC 58.27
- ROIV N/A
- EPS
- GNRC 5.74
- ROIV N/A
- Revenue
- GNRC $4,348,682,000.00
- ROIV $29,053,000.00
- Revenue This Year
- GNRC $5.47
- ROIV $3.28
- Revenue Next Year
- GNRC $6.75
- ROIV $156.84
- P/E Ratio
- GNRC $25.58
- ROIV N/A
- Revenue Growth
- GNRC 8.07
- ROIV N/A
- 52 Week Low
- GNRC $99.50
- ROIV $8.73
- 52 Week High
- GNRC $195.94
- ROIV $13.06
- Technical
- Relative Strength Index (RSI)
- GNRC 61.66
- ROIV 52.70
- Support Level
- GNRC $147.07
- ROIV $10.71
- Resistance Level
- GNRC $154.26
- ROIV $11.58
- Average True Range (ATR)
- GNRC 3.69
- ROIV 0.31
- MACD
- GNRC -0.09
- ROIV 0.02
- Stochastic Oscillator
- GNRC 62.25
- ROIV 60.93
About GNRC Generac Holdlings Inc.
Generac designs and manufactures power generation equipment serving residential, commercial, and industrial markets. It offers standby generators, portable generators, lighting, outdoor power equipment, and a suite of clean energy products. Sales generated in the United States account for the majority of total sales.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.